SCHEMBL10175014

SCHEMBL10175014

CCOC(=O)Cc1ccnc(Cl)n1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
KMT2A Q03164 6/20 0.44
MEN1 O00255 5/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
RAB9A P51151 1/20 0.43
CFTR P13569 1/20 0.43
KDM4E B2RXH2 4/20 0.42
GAA P10253 1/20 0.42
ALDH1A1 P00352 2/20 0.41
POLB P06746 1/20 0.41
LMNA P02545 3/20 0.40
HSD17B10 Q99714 1/20 0.40
HPGD P15428 1/20 0.40
FPR1 P21462 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7676108 0.85 CYP4F2 (0.45) MAPTKDM4EALDH1A1LMNAHSD17B10
SCHEMBL17618001 0.84 ALDH1A1 (0.45) MAPTSMN1; SMN2KMT2AMEN1RAB9A
SCHEMBL21431051 0.84 KMT2A (0.47) MAPTSMN1; SMN2KMT2AMEN1RAB9A
SCHEMBL15820785 0.82 TNF (0.43) MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9
SCHEMBL20241557 0.81 MEN1 (0.48) MAPTSMN1; SMN2KMT2AMEN1RAB9A
SCHEMBL31422596 0.79 KMT2A (0.43) MAPTSMN1; SMN2KMT2AMEN1CYP2C9
SCHEMBL19915712 0.78 MAPT (0.46) MAPTSMN1; SMN2KMT2AMEN1RAB9A
SCHEMBL20165978 0.78 KDM4E (0.54) MAPTSMN1; SMN2KMT2AMEN1RAB9A
SCHEMBL17653827 0.78 POLB (0.46) MAPTSMN1; SMN2KMT2AMEN1CYP1A2
SCHEMBL25854880 0.77 MAPT (0.45) MAPTSMN1; SMN2KMT2AMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630528-B2 Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof LG CHEM, LTD. (KR) 2026-05-19 US disclosed
US-12630515-B2 Small molecule prostagladin transport inhibitors ALBERT EINSTEIN COLLEGE OF MEDICINE (US) 2026-05-19 US disclosed
WO-2025072462-A1 SULFONAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS NIKANG THERAPEUTICS, INC. (US) 2025-04-03 WO disclosed
EP-4071147-B1 NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF LG CHEMICAL LTD (KR) 2025-03-26 EP disclosed
EP-3778576-B1 2-CYANOPYRIMIDIN-4-YL CARBAMATE OR UREA DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME HANLIM PHARMACEUTICAL CO LTD (KR) 2024-04-17 EP disclosed
CN-117659020-A Imidazo [1,2-b ] pyridazine derivative, and preparation method and application thereof 苏州朗睿生物医药有限公司 2024-03-08 CN disclosed
US-20230078941-A1 NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF LG CHEM, LTD. (KR) 2023-03-16 US disclosed
US-20220402881-A1 SMALL MOLECULE PROSTAGLADIN TRANSPORT INHIBITORS ALBERT EINSTEIN COLLEGE OF MEDICINE 2022-12-22 US disclosed
US-20220402881-A1 SMALL MOLECULE PROSTAGLADIN TRANSPORT INHIBITORS ALBERT EINSTEIN COLLEGE OF MEDICINE 2022-12-22 US disclosed
US-20220348571-A1 DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES JANSSEN SCIENCES IRELAND UNLIMITED CO (US) 2022-11-03 US disclosed
CN-105683168-A Arylamino pyramidine compound and application thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom 上海海雁医药科技有限公司 2016-06-15 CN disclosed
WO-2016044781-A1 QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2016-03-24 WO disclosed
US-20160083365-A1 QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2016-03-24 US disclosed
WO-2015127873-A1 ARYLAMINO PYRAMIDINE COMPOUND AND APPLICATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM 上海海雁医药科技有限公司 2015-09-03 WO disclosed
US-8722687-B2 Imidazo [1,2-A]pyridine derivatives as FGFR kinase inhibitors for use in therapy ASTEX THERAPEUTICS LTD (GB) 2014-05-13 US disclosed
US-8722687-B2 Imidazo [1,2-A]pyridine derivatives as FGFR kinase inhibitors for use in therapy ASTEX THERAPEUTICS LTD (GB) 2014-05-13 US disclosed
EP-2691379-A1 HERBICIDALLY AND FUNGICIDALLY ACTIVE 3-PHENYLISOXAZOLINE-5-CARBOXAMIDES AND 3-PHENYLISOXAZOLINE-5-THIOAMIDES Bayer Intellectual Property GmbH (DE) 2014-02-05 EP disclosed
WO-2012130798-A1 HERBICIDALLY AND FUNGICIDALLY ACTIVE 3-PHNEYLISOXAZOLINE-5-CARBOXAMIDES AND 3-PHNEYLISOXAZOLINE-5-THIOAMIDES BAYER CROPSCIENCE AG (DE) 2012-10-04 WO disclosed
US-20120041000-A1 IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY ASTEX THERAPEUTICS LIMITED (GB) 2012-02-16 US disclosed
US-20120041000-A1 IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY ASTEX THERAPEUTICS LIMITED (GB) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041000-A1 IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY FGFR1, FGFR3, FGFR2 MAPT 2571/4885SMN1; SMN2 3124/4885KMT2A 1043/4885
US-20220348571-A1 DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES DPYD, HAVCR2, TYMP MAPT 4190/4885SMN1; SMN2 4699/4885KMT2A 3463/4885
US-20220402881-A1 SMALL MOLECULE PROSTAGLADIN TRANSPORT INHIBITORS PTGER1, PTGIS, PTGIR MAPT 3079/4885SMN1; SMN2 3813/4885KMT2A 4184/4885
US-20230078941-A1 NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF DGAT2, DGAT1, PLAAT2 MAPT 2601/4885SMN1; SMN2 4758/4885KMT2A 421/4885
US-12630528-B2 Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof DGAT2, DGAT1, SOAT2 MAPT 4476/4885SMN1; SMN2 4619/4885KMT2A 889/4885
US-12630515-B2 Small molecule prostagladin transport inhibitors PTGER1, PTGS1, PTGIR MAPT 4183/4885SMN1; SMN2 3550/4885KMT2A 4139/4885
US-20160083365-A1 QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS IDH1, IDH3A, IDH3B MAPT 2189/4885SMN1; SMN2 2149/4885KMT2A 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.